CAMBRIDGE, Mass., September 1, 2016 -- Mersana Therapeutics, Inc., today announced that the Company will present corporate overviews at two upcoming conferences in September:
- Baird’s 2016 Global Healthcare Conference on Thursday, September 8, 2016 at 2:35 p.m. ET in New York City; by Anna Protopapas, President and Chief Executive Officer
- NewsMakers in the Biotech Industry Conference on Friday, September 9, 2016 at 2:30 p.m. ET in New York City; by Anna Protopapas, President and Chief Executive Officer
About Mersana Therapeutics
Mersana Therapeutics is advancing a proprietary pipeline of targeted oncology therapeutics leveraging its game-changing Fleximer® immunoconjugate technology. Mersana's product candidates XMT-1522 and XMT-1536 have the potential to address significant unmet needs and improve patient outcomes in multiple oncology indications. Fleximer-based immunoconjugate molecules have been shown to have superior efficacy, including with targets previously considered not amenable to antibody-drug conjugate approaches. Mersana has collaborations utilizing Fleximer technology with Takeda, Merck KGaA, and Asana BioSciences. For more information, please visit www.mersana.com.
Stern Investor Relations, Inc.